Seminars in Oncology
Volume 29, Issue 2 , Pages 136-144 , April 2002

Transarterial perfusion of liver metastases

References 

  1. Yoon SS, Tanabe KK. Surgical treatment and other regional treatments for colorectal cancer liver metastases. Oncologist. 1999;4:197–208
  2. Choti MA, Bulkley GB. Management of hepatic metastases. Liver Transplant Surg. 1999;5:65–80
  3. Venook AP. Update on hepatic intra-arterial chemotherapy. Oncology. 1997;11:947–970
  4. Meta-Analysis Group in Cancer . Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst. 1996;88:252–258
  5. Harmantas A, Rothstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer. 1996;78:1639–1645
  6. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. Acta Opthalmol Scand. 1995;73:340–344
  7. Gragoudas ES, Egan KM, Seddon JM, et al.  Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383–390
  8. Kath R, Hayungs J, Bornfeld N, et al.  Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219–2223
  9. Mavligit GM, Charnsangavej C, Carrasco CH, et al.  Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA. 1988;260:974–976
  10. Leyvraz S, Spataro V, Bauer J, et al.  Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589–2595
  11. Alexander HR, Allegra CJ, Lawrence TS. Metastatic cancer to the liver. In: ed 6.  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2690–2713
  12. Alexander HR, Bartlett DL, Fraker DL, et al.  Regional treatment strategies for unresectable primary or metastatic cancer confined to the liver. In: ed 4.  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott; 1996;p. 1–19
  13. Breedis C, Young G. Blood supply of neoplasms of the liver. Am J Pathol. 1954;30:969–985
  14. Ridge JA, Sigurdson ER. Distribution of fluorodeoxyuridine uptake in the liver and colorectal hepatic metastases of human beings after arterial infusion. Surg Gynecol Obstet. 1987;164:318–323
  15. Ridge JA, Bading JR, Gelbard AS, et al.  Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer. 1987;59:1547–1553
  16. Alexander HR. Isolation perfusion. In: ed 6.  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer: Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 769–776
  17. Lienard D, Eggermont AM, Kroon BBR, et al.  Isolated limb perfusion in primary and recurrent melanoma: Indications and results. Semin Surg Oncol. 1998;14:202–209
  18. Koops HS, Eggermont AMM, Liénard D, et al.  Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas. Semin Surg Oncol. 1998;14:210–214
  19. Ausman RK. Development of a technique for isolated perfusion of the liver. NY State J Med. 1961;61:3393–3397
  20. Alexander HR, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5:416–424
  21. Alexander , Weinreich DM. Treatment of Unresectable Cancers Confined to Liver Using Vascular Isolation and Perfusion. ed 15. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;
  22. Alexander HR, Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In:  Markman M editors. Current Clinical Oncology: Regional Chemotherapy: Clinical Research and Practice. Totowa, NJ: Humana Press; 1999;p. 127–150
  23. Libutti SK, Bartlett DL, Fraker DL, et al.  Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 2000;191:519–530
  24. Skibba JL, Condon RE. Hyperthermic isolation-perfusion in vivo of the canine liver. Cancer. 1983;51:1303–1309
  25. Skibba JL, Quebbeman EJ. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg. 1986;121:1266–1271
  26. Lienard D, Ewalenko P, Delmotti JJ, et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60
  27. Eggermont AMM, Koops HS, Klausner JM, et al.  Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg. 1996;224:756–765
  28. Alexander HR, Feldman AL. Tumor necrosis factor: Basic principles and clinical application in systemic and regional cancer treatment. In: ed 3.  Steven A,  Rosenberg MD editor. Biologic Therapy of Cancer. Philadelphia, PA: Lippincott; 2000;p. 174–193
  29. Alexander HR, Bartlett DL, Libutti SK, et al.  Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–1489
  30. de Vries MR, Rinkes IH, van de Velde CJ, et al.  Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res. 1998;147:107–119
  31. Hafström L, Naredi P. Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia TNFα and melphalan: Swedish experience. Recent Results Cancer Res. 1998;147:120–126
  32. Oldhafer KJ, Lang H, Frerker M, et al.  First experience and technical aspects of isolated liver perfusion for extensive liver metastasis. Surgery. 1998;123:622–631
  33. Bartlett DL, Libutti SK, Figg WD, et al.  Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129:176–187
  34. Lans TE, Bartlett DL, Libutti SK, et al.  Role of tumor necrosis factor (TNF) on toxicity and cytokine production following isolated hepatic perfusion (IHP). Clin Cancer Res. 2001;7:784–790
  35. Fordy C, Glover C, Davies MM, et al.  Hepatic arterial floxuridine as second-line treatment for systemic fluorouracil-resistant colorectal liver metastases. Br J Cancer. 1998;78:1058–1060
  36. Patt YZ, Hoque A, Lozano R, et al.  Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol. 1997;15:1432–1438
  37. Rajpal S, Moore R, Karakousis CP. Survival in metastatic ocular melanoma. Cancer. 1983;52:334–336
  38. Bedikian AY, Legha SS, Mavligit G, et al.  Treatment of uveal melanoma metastatic to the liver. Cancer. 1995;76:1665–1670
  39. Alexander HR, Libutti SK, Bartlett DL, et al.  A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6:3062–3070
  40. Ravikumar TS, Pizzorno G, Bodden W, et al.  Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemoptherapy for unresectable liver tumors. J clin Oncol. 1994;12:2723–2736
  41. Curley SA, Newman RA, Dougherty T, et al.  Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellualr carcinoma: A phase I study. Ann Surg Oncol. 1994;1:389–399
  42. Ku Y, Tominaga M, Iwasaki T, et al.  Percutaneous hepatic venous isolation and extracorporeal charcoal hemoperfusion for high-dose intraarterial chemotherapy in patients with colorectal hepatic metastases. Surg Today. 1996;26:305–313
  43. Hafström L, Engaras B, Holmberg SB, et al.  Treatment of liver metastases from colorectal cancer with hepatic artery occlusion, intraportal 5-fluorouracil infusion, and oral allopurinol. Cancer. 1994;74:2749
  44. Marinelli A, de Brauw LM, Beerman H, et al.  Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastasis confined to the liver. Jpn J Clin Oncol. 1996;26:341–350
  45. van Zuidewign DBW, de Brauw LM, Marinelli A, et al.  Isolated liver perfusion with mitomycin-C or melphalan in patients with hepatic metastases. Soc Surg Oncol. 1993;46:198; (abstr)

☆ Address reprint requests to H. Richard Alexander, MD, Metabolism Section, Surgery Branch, National Cancer Institute, Room 2B07, 10 Center Dr, Bethesda, MD 20892.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0093-7754(02)50134-2

doi: 10.1053/sonc.2002.31681

Seminars in Oncology
Volume 29, Issue 2 , Pages 136-144 , April 2002

Article Tools

* Image Usage & Resolution